Page 51 - 2019_07 resto del Mondo-web

RSV in HCT and hematologic malignancies
scoring index. Transpl Infect Dis. 2017;19(3).
13. Lavergne V, Ghannoum M, Weiss K, Roy J, Beliveau C. Successful prevention of respira- tory syncytial virus nosocomial transmission following an enhanced seasonal infection control program. Bone Marrow Transplant.
2011;46(1):137-142.
14. Kelly SG, Metzger K, Bolon MK, et al.
Respiratory syncytial virus outbreak on an adult stem cell transplant unit. Am J Infect Control. 2016;44(9):1022-1026.
15. Kassis C, Champlin RE, Hachem RY, et al. Detection and control of a nosocomial respi- ratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizum- ab. Biol Blood Marrow Transplant. 2010; 16(9):1265-1271.
16. Jones BL, Clark S, Curran ET, et al. Control of an outbreak of respiratory syncytial virus infection in immunocompromised adults. J Hosp Infect. 2000;44(1):53-57.
17. Inkster T, Ferguson K, Edwardson A, Gunson R, Soutar R. Consecutive yearly outbreaks of respiratory syncytial virus in a haemato-oncology ward and efficacy of infection control measures. J Hosp Infect. 2017;96(4):353-359.
18. Garcia R, Raad I, Abi-Said D, et al. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol. 1997;18(6):412-416.
19. French CE, McKenzie BC, Coope C, et al. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses. 2016;10(4):268-290.
20. Anaissie EJ, Mahfouz TH, Aslan T, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood. 2004;103(5):1611-1617.
21. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22(5):778-782.
22. Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection follow- ing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(4):321- 327.
23. Chakrabarti S, Avivi I, Mackinnon S, et al. Respiratory virus infections in transplant recipients after reduced-intensity condition- ing with Campath-1H: high incidence but low mortality. Br J Haematol. 2002;119 (4):1125-1132.
24. Avetisyan G, Mattsson J, Sparrelid E, Ljungman P. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation. 2009;88(10):1222-1226.
25. Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11(10):781-796.
26. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplanta- tion: the Christie hospital experience. Bone Marrow Transplant. 2003;32(1):73-77.
27. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow trans-
plantation. Bone Marrow Transplant.
2003;31(8):695-700.
28. Martino R, Ramila E, Rabella N, et al.
Respiratory virus infections in adults with hematologic malignancies: a prospective study. Clin Infect Dis. 2003;36(1):1-8.
29. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripher- al blood stem cell transplantation. Bone Marrow Transplant. 2003;32(11):1085-1088.
30. Hong KW, Choi SM, Lee DG, et al. Lower respiratory tract diseases caused by com- mon respiratory viruses among stem cell transplantation recipients: a single center experience in Korea. Yonsei Med J. 2017;58(2):362-369.
31. Waghmare A, Xie H, Kimball L, et al. Supplemental oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus. J Infect Dis. 2017;216(10):1235-1244.
32. Ogimi C, Waghmare AA, Kuypers JM, et al. Clinical significance of human coronavirus in bronchoalveolar lavage samples from hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2017;64(11): 1532-1539.
33. Seo S, Xie H, Leisenring WM, et al. Risk fac- tors for parainfluenza virus lower respirato- ry tract disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(1):163-171.
34. Waghmare A, Xie H, Kuypers J, et al. Human rhinovirus infections in hematopoi- etic cell transplant recipients: risk score for progression to lower respiratory tract infec- tion. Biol Blood Marrow Transplant. 2019;25(5):1011-1021.
35. Salter A, Laoi BN, Crowley B. Molecular epi- demiology of human respiratory syncytial virus subgroups A and B identified in adults with hematological malignancy attending an Irish hospital between 2004 and 2009. J Med Virol. 2011;83(2):337-347.
36. Kami M, Kishi Y, Hamaki T, et al. A prospec- tive surveillance of nosocomial respiratory syncytial virus infection in a hematology ward: a single-center experience in Japan. Int J Hematol. 2001;74(3):357-359.
37. Azzi JM, Kyvernitakis A, Shah DP, et al. Leukopenia and lack of ribavirin predict poor outcomes in patients with haematolog- ical malignancies and respiratory syncytial virus infection. J Antimicrob Chemother. 2018;73(11):3162-3169.
38. Vakil E, Sheshadri A, Faiz SA, et al. Risk fac- tors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. Transpl Infect Dis. 2018;20(6):e12994.
39. El-Bietar J, Nelson A, Wallace G, et al. RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplan- tation. Bone Marrow Transplant. 2016;51(10):1382-1384.
40. Rowan CM, Gertz SJ, Zinter MS, et al. A multicenter investigation of respiratory syn- cytial viral infection in children with hematopoietic cell transplantation. Transpl Infect Dis. 2018;20(3):e12882.
41. Chemaly RF, Ghantoji SS, Shah DP, et al. Respiratory syncytial virus infections in chil- dren with cancer. J Pediatr Hematol Oncol. 2014;36(6):e376-381.
42. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell trans- plant recipients with respiratory syncytial virus infections. J Antimicrob Chemother.
2013;68(8):1872-1880.
43. Seo S, Campbell AP, Xie H, et al. Outcome
of respiratory syncytial virus lower respira- tory tract disease in hematopoietic cell trans- plant recipients receiving aerosolized rib- avirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant. 2013;19(4):589-596.
44. Pilie P, Werbel WA, Riddell J IV, Shu X, Schaubel D, Gregg KS. Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transpl Infect Dis. 2015;17(4):551-557.
45. McCarthy AJ, Kingman HM, Kelly C, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant. 1999;24(12):1315-1322.
46. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis. 2013;57(12):1731-1741.
47. Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infec- tions in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19(8):1220-1226.
48. Mendes ET, Ramos J, Peixoto D, et al. An outbreak of respiratory syncytial virus infec- tion in hematopoietic stem cell transplanta- tion outpatients: good outcome without specific antiviral treatment. Transpl Infect Dis. 2013;15(1):42-48.
49. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant. 2001;7 (Suppl):5S-7S.
50. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single- center study and review of the literature. Clin Infect Dis. 2008;46(3):402-412.
51. Campbell AP, Chien JW, Kuypers J, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bron- choalveolar lavage samples, viral RNA detection in serum samples, and clinical out- comes of HCT. J Infect Dis. 2010;201 (9):1404-1413.
52. Mazzulli T, Peret TC, McGeer A, et al. Molecular characterization of a nosocomial outbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward. J Infect Dis. 1999;180(5):1686-1689.
53. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to pre- dict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood. 2014;123(21):3263-3268.
54. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determin- ing progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195-1204.
55. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7 (Suppl):11S-5S.
56. Damlaj M, Bartoo G, Cartin-Ceba R, et al. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transpl Infect Dis. 2016;18(2):216-226.
haematologica | 2019; 104(7)
1329